Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Change in Cash (2018 - 2025)

Historic Change in Cash for Inmune Bio (INMB) over the last 8 years, with Q3 2025 value amounting to -$5.6 million.

  • Inmune Bio's Change in Cash fell 32714.46% to -$5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.8 million, marking a year-over-year increase of 2957.27%. This contributed to the annual value of -$14.9 million for FY2024, which is 845.75% up from last year.
  • Per Inmune Bio's latest filing, its Change in Cash stood at -$5.6 million for Q3 2025, which was down 32714.46% from $14.0 million recorded in Q2 2025.
  • Inmune Bio's 5-year Change in Cash high stood at $45.0 million for Q3 2021, and its period low was -$12.6 million during Q4 2024.
  • Its 5-year average for Change in Cash is $303526.3, with a median of -$5.3 million in 2022.
  • Its Change in Cash has fluctuated over the past 5 years, first surged by 229464.79% in 2021, then tumbled by 75617.39% in 2024.
  • Over the past 5 years, Inmune Bio's Change in Cash (Quarter) stood at -$9.7 million in 2021, then surged by 45.64% to -$5.3 million in 2022, then fell by 13.58% to -$6.0 million in 2023, then tumbled by 111.74% to -$12.6 million in 2024, then skyrocketed by 55.34% to -$5.6 million in 2025.
  • Its last three reported values are -$5.6 million in Q3 2025, $14.0 million for Q2 2025, and -$1.6 million during Q1 2025.